Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like C*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name ndc_number drug_product_description date_introduced_to_market wac_at_introduction marketing_pricing_plan_description marketing_pricing_plan_non_public_indicator estimated_number_of_patients breakthrough_therapy_indicator priority_review_indicator acquisition_date acquisition_price acquisition_price_non_public_indicator acquisition_price_comment general_comments supporting_documents
Calliditas Therapeutics US Inc. 81749000401 TARPEYO™ (budesonide) delayed release capsules 2022-01-27 14160.0000 None 1 4000 None 1 None None None None Estimated Number of Patients: There is no ICD-10 code for IgA Nephropathy and no IgA Nephropathy patient registry in the state. The estimated IgAN incidence in the US based on native biopsy is 4000 - 4500 IgAN patients. None
Camber Pharmaceuticals, Inc. 31722057960 Maraviroc 150mg 60ct 2022-02-07 1410.8200 None 1 1200000 None None None None None None None None
Camber Pharmaceuticals, Inc. 31722058060 Maraviroc 300mg 60ct 2022-02-07 1410.8200 None 1 1200000 None None None None None None None None
Camber Pharmaceuticals, Inc. 31722087227 Pirfenidone 267mg 270ct 2022-10-01 1800.0000 None 1 100000 None None None None None None None None
Camber Pharmaceuticals, Inc. 31722087390 Pirfenidone 801mg 90ct 2022-10-01 1800.0000 None 1 100000 None None None None None None None None
Camber Pharmaceuticals, Inc. 31722088930 Fingolimod 0.5mg 30ct 2022-10-17 3681.7300 None 1 1000000 None None None None None None None None
Celltrion USA, Inc. 72606057301 Abiraterone Acetate 500mg 2022-01-21 4219.5400 This product is a generic equivalent of an existing innovator product. Celltrion USA, Inc. does not engage in direct-to-consumer marketing and paid advertising to consumers, physicians, or other healthcare professionals for its generic products. None 4500 None None None None None None None None
Cerona Therapeutics, Inc. 81643927001 Floxuridine; for injection; sterile,nonpyrogenic, lyophilized powder for reconstitution; Each vial (packaged individually) contains 500 mg of floxuridine to be reconstituted with 5 mL of sterile water for injection 2022-06-27 3350.0000 None 1 1000 None None None None None None None None
Chiesi USA 10122050201 Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection 2022-04-18 11245.5900 None 1 47 None 1 2020-11-24 None 1 Private company deal. Price not released. New NDC reflecting manufacturer's labeler code. None
Cipla USA, Inc. 69097087067 Lanreotide Injection 120mg/0.5ml Syringe 1ct 2022-01-31 8892.6600 None 1 175000 None None None None None None Product was not acquired None
Cipla USA, Inc. 69097093698 Lanthanum Carbonate Chew Tabs 1000mg 90's 2022-02-25 971.4800 None 1 558060 None 1 None None None None Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. None
Cipla USA, Inc. 69097093498 Lanthanum Carbonate Chew Tabs 500 mg 90's 2022-02-25 971.4800 None 1 558060 None 1 None None None None Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. None
Cipla USA, Inc. 69097093598 Lanthanum Carbonate Chew Tabs 750mg 90's 2022-02-25 971.4800 None 1 558060 None 1 None None None None Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. None
Cipla USA, Inc. 69097098793 Pirfenidone Tabs 267mg 270ct 2022-08-16 1800.0000 None 1 100000 1 None 2022-05-11 None 1 Drug is licensed from another manufacturer, acquisition price represents licensing cost None None
Cipla USA, Inc. 69097098805 Pirfenidone Tabs 801mg 90ct 2022-08-16 1800.0000 None 1 100000 1 None 2022-05-11 None 1 Drug is licensed from another manufacturer, acquisition price represents licensing cost None None
Cipla USA, Inc. 69097038273 Lenalidomide Capsules 10mg 28 count 2022-09-08 20157.3600 None 1 34000 1 None None None None None None None
Cipla USA, Inc. 69097038381 Lenalidomide Capsules 15 mg 21 count 2022-09-08 15118.0400 None 1 34000 1 None None None None None None None
Cipla USA, Inc. 69097038581 Lenalidomide Capsules 25mg 21 count 2022-09-08 15118.0400 None 1 34000 1 None None None None None None None
Cipla USA, Inc. 69097038173 Lenalidomide Capsules 5mg 28’s 2022-09-08 20157.3600 None 1 34000 1 None None None None None None None
Cipla USA, Inc. 69097090950 Leuprolide acetate suspension 22.5mg/2ml syringe 2022-11-22 1355.0700 None 1 270000 None None None None None None drug not acquired None
CMP Pharma 46287004515 Tadalafil oral suspension, 20mg.5 mL, 150 mL bottle 2022-10-12 1895.0000 None 1 1000 None None None None None None None None
Coherus BioSciences, Inc. 70114044001 Each CIMERLI 0.3 mg carton contains a single-dose, 2-mL glass vial with a WHITE CAP designed to deliver 0.05 mL of 6 mg/mL ranibizumab-eqrn solution 2022-10-03 816.0000 None 1 1621598 None None None None None None None None
Coherus BioSciences, Inc. 70114044101 Each CIMERLI 0.5 mg carton contains a single-dose, 2-mL glass vial with a BLUE CAP designed to deliver 0.05 mL of 10 mg/mL ranibizumab-eqrn solution. 2022-10-03 1360.0000 None 1 1621598 None None None None None None None None
CTI BioPharma Corp. 72482010012 VONJO 100 mg capsule, 120 capsules 2022-03-10 19500.0000 VONJO will be promoted by our commercial field team to healthcare professionals to educate them on our product. We will use various means of promotion including in-office visits, virtual meetings, ad campaigns, and digital marketing. Pricing was established by CTI BioPharma Corp. after conducting extensive market research and analysis, which included the research and development investment made, forecasted operational costs, and the overall competitive landscape to reach our determination of launch WAC price. Our launch WAC price is intended to reflect the drug’s specific value to patients within our indicated population and the healthcare providers who treat them. None 7000 None 1 None None None None None None